Microorganisms universally attach to surfaces, resulting in biofilm formation. These biofilms entail a serious problem in daily clinical practice because of the great prevalence of implantable device-related infections. Differences in antibiotic activity against planktonic and sessile bacteria may relate to clinical failures in the treatment of biofilm-related infections (BRI). Bacteriophages have several characteristics that make them potentially attractive therapeutic agents in some selected clinical settings, like for example BRI. They are highly specific and very effective in lysing targeted bacteria, moreover, they appear to be safe for humans. Many studies have shown the potential of phages for the treatment of infectious diseases in plants and animals, including infections with highly drug-resistant bacteria. The therapeutic use of bacteriophages, possibly in combination with antibiotics, may be a valuable approach in BRI. However, many important questions still remain that must be addressed before phages can be endorsed for therapeutic use in humans.
CostertonJ.W., StewartP.S., GreenbergE.P.Bacterial biofilms: a common cause of persistent infections. Science1999; 284: 1318–22.
2.
DarouicheR.O.Treatment of infections associated with surgical implants. N Engl J Med2004; 350: 1422–9.
3.
StewartP.S., CostertonJ.W.Antibiotic resistance of bacteria in biofilms. Lancet2001; 358: 135–8.
4.
MahT.F., O'TooleG.A.Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol2001; 9: 34–9.
5.
CeriH., OlsonM.E., StremickC., ReadR.R., MorckD., BuretA.The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol1999; 37: 1771–6.
6.
del PozoJ.L., SerreraA., MartínezA., LeivaJ., PenadésJ., LasaI.Biofilm related infections: Is there a place for conservative treatment of port-related bloodstream infections. Int J Artif Organs2006; 29: 379–86.
7.
HuebnerJ., GoldmannD.A.Coagulase-negative staphylococci: role as pathogens. Annu Rev Med1999; 50: 223–36.
8.
CostertonJ.W., MontanaroL., ArciolaC.R.Biofilm in implant infections: its production and regulation. Int J Artif Organs2005; 28: 1062–8. Review
9.
MackD., RohdeH., HarrisL.G., DaviesA.P., HorstkotteM.A., KnoblochJ.K.Biofilm formation in medical device-related infection. Int J Artif Organs2006; 29: 343–59.
10.
von EiffC., ArciolaC.R., MontanaroL., BeckerK., CampocciaD.Emerging Staphylococcus species as new pathogens in implant infections. Int J Artif Organs2006; 29: 360–7. Review.
11.
ArciolaC.R., CampocciaD., AnY.H., BaldassarriL., PiriniV., DonatiM.E., PegreffiF., Montanaro Prevalence and antibiotic resistance of 15 minor staphylococcal species colonizing orthopedic implants. Int J Artif Organs2006; 29: 395–401.
12.
ArciolaC.R., AlviF.I., AnY.H., CampocciaD., MontanaroL.Implant infection and infection resistant materials: a mini review. Int J Artif Organs2005; 28: 1119–25. Review.
13.
ReidG.Biofilms in infectious disease and on medical devices. Int J Antimicrob Agents1999; 11: 223–6.
14.
RichardP., Le FlochR., ChamouxC., PannierM., EspazeE., RichetH.Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. J Infect Dis1994; 170: 377–83.
OgunseitanO.A., SaylerG.S., MillerR.V.Application of DNA probes to analysis of bacteriophage distribution patterns in the environment. Appl Environ Microbiol1992; 58: 2046–52.
18.
SkurnikM., StrauchE.Phage therapy: facts and fiction. Int J Med Microbiol2006; 296: 5–14.
19.
ThielK.Old dogma, new tricks–21st Century phage therapy. Nat Biotechnol2004; 22: 31–6.
20.
SulakvelidzeA., MorrisJ.G.Jr.. Bacteriophages as therapeutic agents. Ann Med2001; 33: 507–9.
21.
AhmadS.I.Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics. Med Hypotheses2002; 58: 327–31.
22.
DixonB.New dawn for phage therapy. Lancet Infect Dis2004; 4: 186.
23.
SulakvelidzeA.Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections. Drug Discov Today2005; 10: 807–9.
24.
ChernomordikA.B.[Bacteriophages and their therapeutic-prophylactic use]. Med Sestra1989; 48: 44–7.
25.
SmithH.W., HugginsM.B.Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol1982; 128: 307–18.
26.
HagensS., HabelA., von AhsenU., von GabainA., BlasiU.Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother2004; 48: 3817–22.
SlopekS., Weber-DabrowskaB., DabrowskiM., Kucharewicz-KrukowskaA.Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz)1987; 35: 569–83.
29.
D'HerelleF.The Bacteriophage and its behavior.Baltimore: Williams and Wilkins1926.
30.
BogovazovaG.G., VoroshilovaN.N., BondarenkoV.M.[The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection]. Zh Mikrobiol Epidemiol Immunobiol1991; 4: 5–8.
31.
SoothillJ.S.Treatment of experimental infections of mice with bacteriophages. J Med Microbiol1992; 37: 258–61.
32.
TanjiY., ShimadaT., FukudomiH., MiyanagaK., NakaiY., UnnoH.Therapeutic use of phage cocktail for controlling Escherichia coli O157: H7 in gastrointestinal tract of mice. J Biosci Bioeng2005; 100: 280–7.
33.
WangJ., HuB., XuM., YanQ., LiuS., ZhuX.Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med2006; 17: 309–17.
34.
WoodH.L., HoldenS.R., BaystonR.Susceptibility of Staphylococcus epidermidis biofilm in CSF shunts to bacteriophage attack. Eur J Pediatr Surg2001; 11(Suppl 1): S56–7.
35.
MathurM.D., VidhaniS., MehndirattaP.L.Bacteriophage therapy: an alternative to conventional antibiotics. J Assoc Physicians India2003; 51: 593–6.
36.
MatsuzakiS., RashelM., UchiyamaJ., SakuraiS., UjiharaT., KurodaM.Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chef-mother2005; 11: 211–9.
37.
SillankorvaS., OliveiraR., VieiraM.J., SutherlandI.W., AzeredoJ.Bacteriophage Phi S1 infection of Pseudomonas fluorescens planktonic cells versus biofilms. Biofouling2004; 20: 133–8.
38.
WebbJ.S., LauM., KjellebergS.Bacteriophage and phenotypic variation in Pseudomonas aeruginosa biofilm development. J Bacteriol2004; 186: 8066–73.
39.
SutherelandI.W., HughesK.A., SkillmanL.C., TaitK.The interaction of phage and biofilms. FEMS Microbiol Lett2004; 232: 1–6.
40.
StanleyN.R., LazazzeraB.A.Environmental signals and regulatory pathways that influence biofilm formation. Mol Microbiol2004; 52: 917–24.
41.
McLeanR.J., CorbinB.D., BalzerG.J., AronG.M.Phenotype characterization of genetically defined microorganisms and growth of bacteriophage in biofilms. Methods Enzymol2001; 336: 163–74.
42.
WeinerR., LangilleS., QuinteroE.Structure, function and immunochemistry of bacterial exopolysaccharides. J Ind Microbiol1995; 15: 339–46.
43.
PelkonenS., AaltoJ., FinneJ.Differential activities of bacteriophage depolymerase on bacterial polysaccharide: binding is essential but degradation is inhibitory in phage infection of K1-defective Escherichia coli. J Bacteriol1992; 174: 7757–61.
44.
BayerM.E., ThurowH., BayerM.H.Penetration of the polysaccharide capsule of Escherichia coli (Bi161/42) by bacteriophage K29. Virology1979; 94: 95–118.
45.
HughesK.A., SutherlandI.W., JonesM.V.Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase. Microbiology1998; 144(Pt 11): 3039–47.
46.
CorbinB.D., McLeanR.J., AronG.M.Bacteriophage T4 multi-plication in a glucose-limited Escherichia coli biofilm. Can J Microbiol2001; 47: 680–4.
47.
CurtinJ.J., DonlanR.M.Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother2006; 50: 1268–75.
StepanovicS., VukovicD., DakicI., SavicB., Svabic-VlahovicM.A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods2000; 40: 175–9.
50.
BogovazovaG.G., VoroshilovaN.N., BondarenkoV.M., GorbatkovaG.A., Afanas'evaE.V., KazakovaT.B.[Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages]. Zh Mikrobiol Epidemiol Immunobiol1992; 30–3.
51.
PayneR.J., JansenV.A.Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol2001; 208: 37–48.
52.
KasmanL.M., KasmanA., WestwaterC., DolanJ., SchmidtM.G., NorrisJ.S.Overcoming the phage replication threshold: a mathematical model with implications for phage therapy. J Virol2002; 76: 5557–64.
53.
InchleyC.J.The actvity of mouse Kupffer cells following in-travenous injection of T4 bacteriophage. Clin Exp Immunol1969; 5: 173–87.
54.
Weber-DabrowskaB., DabrowskiM., SlopekS.Studies on bacteriophage penetration in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz)1987; 35: 563–8.
55.
BabalovaE.G., KatsitadzeK.T., SakvarelidzeL.A., ImnaishviliN., SharashidzeT.G., BadashviliV.A.[Preventive value of dried dysentery bacteriophage]. Zh Mikrobiol Epidemiol Immunobiol1968; 45: 143–5.
56.
BruttinA., BrussowH.Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother2005; 49: 2874–8.
57.
BrüssowH., CanchayaC., HardtW.D.Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol Mol Biol Rev2004; 68: 560–602.
58.
McGrathS., FitzgeraldG.F., van SinderenD.The impact of bacteriophage genomics. Curr Opin Biotechnol2004; 15: 94–9.
59.
Kucharewicz-KrukowskaA., SlopekS.Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz)1987; 35: 553–61.
